Think Research Corp (TSXV:THNK)

C$ 0.315 0 (0%) Market Cap: 24.82 Mil Enterprise Value: 71.97 Mil PE Ratio: 0 PB Ratio: 0.88 GF Score: 16/100

Q2 2023 Think Research Corporation Earnings Call Transcript
Aug 29, 2023

C$0.31 (+6.90%)

Earnings
Q1 2023 Think Research Corporation Earnings Call Transcript
May 30, 2023

C$0.35 (+9.37%)

Earnings
Q4 2022 Think Research Corporation Earnings Call Transcript
May 01, 2023

C$0.35 (-18.60%)

Earnings
Think Research Corporation at Bloom Burton & Co Healthcare Investor Conference Transcript
Apr 26, 2023
Q3 2022 Think Research Corporation Earnings Call Transcript
Nov 28, 2022

C$0.32 (-8.57%)

Earnings
Q2 2022 Think Research Corporation Earnings Call Transcript
Aug 29, 2022

C$0.66 (-12.00%)

Earnings
Think Research Corporation at GCFF Global Chinese Financial Conference -- Healthcare Investment North America (Virtual) Transcript
Jun 16, 2022
Q1 2022 Think Research Corporation Earnings Call Transcript
May 30, 2022

C$0.7 (+4.48%)

Earnings
Think Research Corporation at Bloom Burton & Co. Healthcare Investor Conference Transcript
May 03, 2022
Q4 2021 Think Research Corporation Earnings Call Transcript
May 02, 2022

C$0.8 (-4.76%)

Earnings
Think Research Corporation SNN Network Webcast Transcript
Dec 30, 2021
Think Research Corporation at Desjardins Digital Healthcare Conference (Virtual) Transcript
Nov 30, 2021
Q3 2021 Think Research Corporation Earnings Call Transcript
Nov 29, 2021

C$1.57 (+3.29%)

Earnings
Q2 2021 Think Research Corporation Earnings Call Transcript
Aug 23, 2021

Earnings

Think Research Corporation at GCFF Global Chinese Financial Conference -- Healthcare Investment North America (Virtual) Transcript

Jun 16, 2022 / 03:25PM GMT

Release Date Price: C$0.52 (-8.77%)

Transcript

Sachin Aggarwal

Think Research Corporation - CEO

Thanks, Gilbert. And thanks for having us, everyone. Thanks for joining us this morning. My name is Sachin Aggarwal, the CEO of Think Research.

And what we do, we are a software company. And what we do is we get new clinical evidence and new clinical knowledge into the hands of doctors, nurses, and pharmacists through enterprise relationships. So these are relationships with -- these are licenses with clinics, with hospitals, with entire government. We then deploy our solutions to those doctors, nurses, and pharmacists so they can practice up-to-date medicine.

As Gilbert said, our mission is to organize the world's health knowledge so everyone gets the best care, okay? So essentially, new evidence, new knowledge to the bedside so patients get better care. What we do -- what we are to our clients is an essential data service for the clinicians.

Gilbert mentioned a few of our stats. We are on track for a run rate of approximately CAD91 million by the end of fiscal 2022. And just again, more than 300,000 clinicians -- that's

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.